6.89
0.36 (5.51%)
| Previous Close | 6.53 |
| Open | 7.06 |
| Volume | 16,846,074 |
| Avg. Volume (3M) | 4,770,360 |
| Market Cap | 2,456,360,704 |
| Price / Earnings (Forward) | 50.00 |
| Price / Sales | 30.35 |
| Price / Book | 57.51 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,685.01% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 35.04% |
| Current Ratio (MRQ) | 3.53 |
| Operating Cash Flow (TTM) | -70.41 M |
| Levered Free Cash Flow (TTM) | -53.20 M |
| Return on Assets (TTM) | -44.04% |
| Return on Equity (TTM) | -278.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Precigen, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -4.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -1.50 |
|
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.56% |
| % Held by Institutions | 67.08% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SHAH RUTUL R | - | 6.76 | -66,511 | -449,459 |
| Aggregate Net Quantity | -66,511 | |||
| Aggregate Net Value ($) | -449,459 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 6.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SHAH RUTUL R | Officer | 06 Aug 2026 | Automatic sell (-) | 32,739 | 6.91 | 226,226 |
| SHAH RUTUL R | Officer | 03 Aug 2026 | Automatic sell (-) | 33,772 | 6.61 | 223,233 |
| SHAH RUTUL R | Officer | 03 Aug 2026 | Option execute | 33,772 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |